-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Lowers Price Target to $27

Benzinga·10/08/2026 10:32:05
Listen to the news
HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $47 to $27.